Barrington analyst Michael Petusky raised the firm’s price target on Haemonetics to $114 from $111 and keeps an Outperform rating on the shares after increasing the firm’s non-GAAP EPS estimates for both FY24 and FY25 following the company’s quarterly beat and guidance raise.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HAE:
- Haemonetics raises FY24 adjusted EPS view to $3.60-$3.90 from $3.45-$3.75
- Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
- Haemonetics reports Q1 adjusted EPS $1.05, consensus 73c
- HAE Earnings this Week: How Will it Perform?
- Haemonetics receives FDA clearance for NexSys PCS plasma collection system
